New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
09:10 EDTSUPNSupernus announces issuance of first use patents for SPN-812
Supernus Pharmaceuticals announced the issuance of a European patent and Canadian patent for SPN-812, its novel non-stimulant product candidate for the treatment of ADHD. These patents will provide protection for the product with expiration that is no earlier than 2029. Supernus has several additional patent applications for SPN-812 pending in other geographic regions, including the United States.
News For SUPN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
09:08 EDTSUPNSupernus announces Paragraph IV ANDA filing for Trokendi XR
Supernus Pharmaceuticals announced that on October 13, the company received a Paragraph IV Notice Letter from Zydus Pharmaceuticals advising Supernus of the filing by Zydus of an Abbreviated New Drug Application seeking approval for topiramate extended-release capsules. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Trokendi XR. The product is currently protected by three issued patents that are listed in the FDA's Orange Book and expire no earlier than 2027.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use